Although many chemotherapy agents and regimens have been studied and used as adjuvant therapy in patients with high-risk early hormone receptor–positive breast cancer, they generally include two of the most active cytotoxic classes of agents in this setting: anthracyclines and taxanes. Many regimens have been evaluated in an effort to achieve highest rates of disease-free and overall survival with the lowest degree of toxicity. Nevertheless, in this setting, some combination of appropriate cytotoxic agents (eg, doxorubicin, cyclophosphamide; paclitaxel or docetaxel) is standard; single-agent treatment (ie, either with 5-fluorouracil or a taxane) is not recommended as adjuvant therapy.
The combination of a platinum agent plus an antifolate, such as cisplatin and pemetrexed, is often used to treat non–small cell lung cancer but is not one of the preferred options for early breast cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Skill Checkup: A Menopausal Woman With a Lump in Her Right Breast - Medscape - Jan 18, 2022.
Comments